No Data
Market bullish stimulus boosts Hong Kong pharmaceutical stocks, with Genshuo Niaoyao rising over 14%.
① What bullish impacts does the medical insurance centralized procurement have on pharmaceutical companies? ② How do institutions view the subsequent development of pharmaceutical stocks?
Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Shanghai Pharmaceuticals' Trial on Drug for Stroke Patients Shows Positive Results
China Securities Co.,Ltd.: In the 2024 version of the medical insurance catalog, the number of innovative drugs added has reached a new high, balancing 'ensuring basic coverage' and 'supporting genuine innovation'.
Overall situation of the 2024 medical insurance catalog: the results are stable, meeting expectations, with a record high in the number of new innovative drugs, reflecting a balanced consideration of fund safety, public medical needs, and support for innovation.
sh pharma (601607.SH): I037 completed the analysis of the results of the phase II clinical trials in china.
Gelonghui November 29th | sh pharma (601607.SH) announced that the company has signed a "Cooperation Agreement" with Shuntian Pharmaceutical Biotechnology Co., Ltd., obtaining the exclusive rights in China to develop, produce, and sell I037 (referred to as "LT3001" or "the project") (see Announcement No. 2019-085. In September 2020, the project was approved by the National Medical Products Administration to conduct clinical trials (see Announcement No. 2020-052). Recently, the company has completed the analysis of the results of the Phase II clinical trial of LT3001 in China. Injection LT300.
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Return Trends At Shanghai Pharmaceuticals Holding (SHSE:601607) Aren't AppealingNo Data
No Data
